Covered recipient · General Payments record
HOPE S RUGO
Allopathic & Osteopathic Physicians Internal Medicine Hematology
A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.
Saved only in this browser. No account or alerts.
General Payments · PY2023 · Entire year
$112,634.17
115 records · 0 disputed
“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”
— Centers for Medicare & Medicaid Services, Open Payments
A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.
These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.
A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.
How these totals are calculated
- This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Methodology & Data — sourcing, labeling, and limitations.
Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗
By nature of payment
PY2023 · entire year · sorted by reported total
| Nature of payment | Amount | Records |
|---|---|---|
| Travel and Lodging | $82,120.09 | 34 |
| Consulting Fee | $19,435.98 | 7 |
| Food and Beverage | $6,100.47 | 72 |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $4,977.63 | 2 |
By paying entity
PY2023 · entire year · sorted by reported total
| Paying entity | Amount | Records |
|---|---|---|
| PFIZER INC. | $21,895.38 | 27 |
| Gilead Sciences, Inc. | $20,714.81 | 27 |
| Merck Sharp & Dohme LLC | $19,311.15 | 18 |
| Chugai Pharmaceutical Co., Ltd. | $18,428.20 | 4 |
| Napo Pharmaceuticals Inc | $12,000.00 | 4 |
| F. Hoffmann-La Roche AG | $9,699.73 | 3 |
| Mylan Inc. | $3,920.00 | 1 |
| AstraZeneca Pharmaceuticals LP | $2,735.94 | 12 |
| Puma Biotechnology, Inc. | $1,300.00 | 1 |
| Boehringer Ingelheim International GmbH | $1,057.63 | 1 |
| Stemline Therapeutics Inc. | $568.66 | 5 |
| AstraZeneca UK Limited | $429.69 | 6 |
| Genentech USA, Inc. | $344.31 | 3 |
| Coherus Biosciences Inc. | $228.67 | 3 |
Page 2 of 3; records 51–100 of 115 matching records. This page contains 50 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.
IndustryPayments · General Payments
HOPE S RUGO
NPI 1033176581 · CMS profile ID 183398
Allopathic & Osteopathic Physicians / Internal Medicine / Hematology
SAN FRANCISCO, CA
A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.
A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.
General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types
Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00
Page 2 of 3; records 51–100 of 115 matching records. This page contains 50 records (maximum 50), not the full filtered export.
Filtered page: https://industrypayments.org/provider/npi-1033176581?year=2023&recipient=provider&page=2#records-h
CMS source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9
Cite these filtered records
The citation includes this program year, filters, data edition, and page of results.
- Plain
- HOPE S RUGO, NPI 1033176581, CMS profile ID 183398. General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 3; records 51–100 of 115 matching records. This page contains 50 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1033176581?year=2023&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9.
- APA 7
- IndustryPayments. (2026). HOPE S RUGO, NPI 1033176581, CMS profile ID 183398. General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 3; records 51–100 of 115 matching records. This page contains 50 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1033176581?year=2023&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9.
- Bluebook
- HOPE S RUGO, NPI 1033176581, CMS profile ID 183398, IndustryPayments, General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 2 of 3; records 51–100 of 115 matching records. This page contains 50 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9. https://industrypayments.org/provider/npi-1033176581?year=2023&recipient=provider&page=2#records-h.
Centers for Medicare & Medicaid Services, Open Payments
Citation formats are provided for reference; check the requirements of your publication.
Payment records · PY2023
Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them
General Payments · PY2023 · Physicians and non-physician practitioners · CMS publication 2026-06-30
115 matching records · $112,634.17 reported total · 0 disputed
Nature of payment: All payment types
Records imported here (UTC).
CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.
Showing records 51–100 of 115.
| Paying entity | Amount | Date | Nature of payment | Dispute status | Publication flags | Published | Record ID | Source |
|---|---|---|---|---|---|---|---|---|
| Gilead Sciences, Inc. | $111.01 | 08/18/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1025519509 | CMS |
| PFIZER INC. | $34.64 | 08/17/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1050473677 | CMS |
| Gilead Sciences, Inc. | $85.17 | 08/15/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1025526451 | CMS |
| PFIZER INC. | $106.45 | 08/15/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1049127607 | CMS |
| Stemline Therapeutics Inc. | $85.16 | 08/15/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1040027301 | CMS |
| PFIZER INC. | $303.95 | 08/02/2023 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1050688535 | CMS |
| Gilead Sciences, Inc. | $114.34 | 07/29/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1025518091 | CMS |
| Gilead Sciences, Inc. | $23.32 | 07/29/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1025698181 | CMS |
| Gilead Sciences, Inc. | $85.68 | 07/17/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1025526405 | CMS |
| Coherus Biosciences Inc. | $45.84 | 07/15/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1060237987 | CMS |
| Boehringer Ingelheim International GmbH | $1,057.63 | 07/13/2023 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1017329341 | CMS |
| Stemline Therapeutics Inc. | $146.81 | 07/13/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1040027305 | CMS |
| AstraZeneca Pharmaceuticals LP | $65.96 | 07/03/2023 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1011292325 | CMS |
| AstraZeneca Pharmaceuticals LP | $800.60 | 07/03/2023 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1012083085 | CMS |
| AstraZeneca Pharmaceuticals LP | $1,150.80 | 07/03/2023 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1014668253 | CMS |
| Chugai Pharmaceutical Co., Ltd. | $6,080.00 | 06/29/2023 | Consulting Fee | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1040378493 | CMS |
| Chugai Pharmaceutical Co., Ltd. | $197.96 | 06/29/2023 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1040378499 | CMS |
| Chugai Pharmaceutical Co., Ltd. | $105.90 | 06/29/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1040378505 | CMS |
| Chugai Pharmaceutical Co., Ltd. | $12,044.34 | 06/29/2023 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1040378511 | CMS |
| Napo Pharmaceuticals Inc | $3,000.00 | 06/12/2023 | Consulting Fee | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1062029634 | CMS |
| Gilead Sciences, Inc. | $132.57 | 06/04/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1025504415 | CMS |
| AstraZeneca UK Limited | $44.99 | 06/03/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1016996931 | CMS |
| AstraZeneca Pharmaceuticals LP | $75.00 | 06/02/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1014523635 | CMS |
| AstraZeneca Pharmaceuticals LP | $25.00 | 06/02/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1015185333 | CMS |
| AstraZeneca UK Limited | $24.99 | 06/01/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1017050545 | CMS |
| AstraZeneca UK Limited | $49.99 | 06/01/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1017074707 | CMS |
| Coherus Biosciences Inc. | $55.98 | 06/01/2023 | Consulting Fee | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1060238029 | CMS |
| PFIZER INC. | $73.51 | 05/19/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1049457189 | CMS |
| PFIZER INC. | $276.97 | 05/13/2023 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1049287171 | CMS |
| AstraZeneca Pharmaceuticals LP | $76.46 | 05/12/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1011718587 | CMS |
| Merck Sharp & Dohme LLC | $261.80 | 05/12/2023 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1048282875 | CMS |
| PFIZER INC. | $33.48 | 05/12/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1049404343 | CMS |
| PFIZER INC. | $115.68 | 05/12/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1050630703 | CMS |
| Merck Sharp & Dohme LLC | $261.80 | 05/11/2023 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1048282721 | CMS |
| Merck Sharp & Dohme LLC | $8,094.65 | 05/10/2023 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1048282725 | CMS |
| Merck Sharp & Dohme LLC | $215.41 | 05/10/2023 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1048723577 | CMS |
| Merck Sharp & Dohme LLC | $261.80 | 05/10/2023 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1048723585 | CMS |
| PFIZER INC. | $131.15 | 05/10/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1050387807 | CMS |
| PFIZER INC. | $6.23 | 05/06/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1050666349 | CMS |
| Merck Sharp & Dohme LLC | $102.94 | 05/05/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1048386009 | CMS |
| Coherus Biosciences Inc. | $126.85 | 04/22/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1060237971 | CMS |
| F. Hoffmann-La Roche AG | $546.40 | 04/21/2023 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1040378517 | CMS |
| F. Hoffmann-La Roche AG | $317.01 | 04/21/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1040378523 | CMS |
| F. Hoffmann-La Roche AG | $8,836.32 | 04/21/2023 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1040378529 | CMS |
| PFIZER INC. | $66.82 | 03/18/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1049381099 | CMS |
| PFIZER INC. | $112.69 | 03/17/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1050658825 | CMS |
| Napo Pharmaceuticals Inc | $3,000.00 | 03/16/2023 | Consulting Fee | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1062029632 | CMS |
| PFIZER INC. | $131.94 | 03/15/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1050530383 | CMS |
| Merck Sharp & Dohme LLC | $67.08 | 03/14/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1048386001 | CMS |
| Merck Sharp & Dohme LLC | $56.00 | 03/14/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1048386005 | CMS |
By program year
All program years on this page · sorted by year
Source & provenance
- Dataset
- CMS Open Payments — General Payments
- Publisher of source data
- Centers for Medicare & Medicaid Services
- CMS publication date
- 2026-06-30
- Program years on this page
- 2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
- Source files
- Dataset page · Bulk file · PY2019 , PY2020 , PY2021 , PY2022 , PY2023 , PY2024 , PY2025
- Generated from
- OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.
Research Payments
One row per program year and role, newest year first · amounts for the two roles are never added together
| Program year | Role | Amount | Records |
|---|---|---|---|
| PY2025 | Recipient | $26,640.31 | 21 |
| PY2025 | Principal investigator | $1,762,718.60 | 127 |
| PY2024 | Recipient | $32,716.33 | 18 |
| PY2024 | Principal investigator | $3,878,535.88 | 120 |
| PY2023 | Recipient | $65,869.73 | 29 |
| PY2023 | Principal investigator | $3,628,374.01 | 141 |
| PY2022 | Recipient | $25,218.00 | 19 |
| PY2022 | Principal investigator | $3,191,632.06 | 99 |
| PY2021 | Recipient | $87,043.55 | 44 |
| PY2021 | Principal investigator | $4,351,047.57 | 136 |
| PY2020 | Recipient | $43,604.90 | 39 |
| PY2020 | Principal investigator | $3,949,955.67 | 243 |
| PY2019 | Recipient | $7,316.88 | 14 |
| PY2019 | Principal investigator | $2,506,017.46 | 241 |
Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.
“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”
— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224
Research Payments records · PY2025
Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them
148 records in PY2025
| Role | Paying entity | Amount | Date | Recipient | Study | Dispute status | Published | Record ID |
|---|---|---|---|---|---|---|---|---|
| Principal investigator 1 | Merck Sharp & Dohme LLC | $34,811.71 | 12/31/2025 | Covered Recipient Teaching Hospital City Of Hope National Medical Ctr | A Phase 3, Randomized, Open-label Study Comparing Efficacy and Safety of Sacituzumab Tirumotecan sac-TMT, MK-2870 as a Monotherapy and in Combination with PembrolizumabMK-3475 Versus Treatment of Physician's Choice in Participants With Previously Untr | No dispute reported | 06/30/2026 | 1232922938 |
| Principal investigator 1 | Merck Sharp & Dohme LLC | $34,811.71 | 12/31/2025 | Covered Recipient Teaching Hospital City Of Hope National Medical Ctr | A Phase 3, Randomized, Open-label Study Comparing Efficacy and Safety of Sacituzumab Tirumotecan sac-TMT, MK-2870 as a Monotherapy and in Combination with PembrolizumabMK-3475 Versus Treatment of Physician's Choice in Participants With Previously Untr | No dispute reported | 06/30/2026 | 1232923662 |
| Principal investigator 1 | Merck Sharp & Dohme LLC | $350.18 | 12/31/2025 | Covered Recipient Teaching Hospital Langley Porter Psychiatric Hospital | A Randomized, Double-Blind, Phase III Study of Pembrolizumab MK-3475 plus Chemotherapy vs Placebo plus Chemotherapy for Previously Untreated Locally Recurrent Inoperable or Metastatic Triple Negative Breast Cancer - KEYNOTE-355 | No dispute reported | 06/30/2026 | 1232925865 |
| Principal investigator 1 | PFIZER INC. | $54.70 | 12/18/2025 | Covered Recipient Teaching Hospital Langley Porter Psychiatric Hospital | PALLASPALBOCICLIB COLLABORATIVE ADJUVANT STUDYA RANDOMIZED PHASE III TRIAL OF PALBOCICLIB WITH STANDARD ADJUVANT ENDOCRINE THERAPY VERSUS STANDARD ADJUVANT ENDOCRINE THERAPY ALONE FOR HR OR HER2 EARLY BREAST CANCER WI203696 | No dispute reported | 06/30/2026 | 1228709476 |
| Principal investigator 1 | PFIZER INC. | $54.70 | 12/18/2025 | Covered Recipient Teaching Hospital Langley Porter Psychiatric Hospital | PALLASPALBOCICLIB COLLABORATIVE ADJUVANT STUDYA RANDOMIZED PHASE III TRIAL OF PALBOCICLIB WITH STANDARD ADJUVANT ENDOCRINE THERAPY VERSUS STANDARD ADJUVANT ENDOCRINE THERAPY ALONE FOR HR OR HER2 EARLY BREAST CANCER WI203696 | No dispute reported | 06/30/2026 | 1228709636 |
| Principal investigator 1 | PFIZER INC. | $54.70 | 12/18/2025 | Covered Recipient Teaching Hospital Langley Porter Psychiatric Hospital | PALLASPALBOCICLIB COLLABORATIVE ADJUVANT STUDYA RANDOMIZED PHASE III TRIAL OF PALBOCICLIB WITH STANDARD ADJUVANT ENDOCRINE THERAPY VERSUS STANDARD ADJUVANT ENDOCRINE THERAPY ALONE FOR HR OR HER2 EARLY BREAST CANCER WI203696 | No dispute reported | 06/30/2026 | 1228709638 |
| Principal investigator 1 | PFIZER INC. | $54.70 | 12/18/2025 | Covered Recipient Teaching Hospital Langley Porter Psychiatric Hospital | PALLASPALBOCICLIB COLLABORATIVE ADJUVANT STUDYA RANDOMIZED PHASE III TRIAL OF PALBOCICLIB WITH STANDARD ADJUVANT ENDOCRINE THERAPY VERSUS STANDARD ADJUVANT ENDOCRINE THERAPY ALONE FOR HR OR HER2 EARLY BREAST CANCER WI203696 | No dispute reported | 06/30/2026 | 1228709800 |
| Principal investigator 1 | PFIZER INC. | $2,177.18 | 12/17/2025 | Covered Recipient Teaching Hospital Langley Porter Psychiatric Hospital | A TREATMENT PROTOCOL FOR PARTICIPANTS CONTINUING FROM PFIZERSPONSORED PALBOCICLIB CLINICAL STUDIES | No dispute reported | 06/30/2026 | 1228709960 |
| Recipient | F. Hoffmann-La Roche AG | $503.68 | 12/12/2025 | Covered Recipient Physician | Phase III study of giredestrant everolimus vs everolimus exemestane in ER HER2 locally adv or mBC | No dispute reported | 06/30/2026 | 1211536059 |
| Recipient | F. Hoffmann-La Roche AG | $292.89 | 12/12/2025 | Covered Recipient Physician | Phase III study of giredestrant everolimus vs everolimus exemestane in ER HER2 locally adv or mBC | No dispute reported | 06/30/2026 | 1211536062 |
| Principal investigator 1 | PFIZER INC. | $53,304.29 | 12/11/2025 | Covered Recipient Teaching Hospital Langley Porter Psychiatric Hospital | A PHASE 1 DOSE ESCALATION AND EXPANSION STUDY TO EVALUATE SAFETY TOLERABILITY PHARMACOKINETIC PHARMACODYNAMIC AND ANTITUMOR ACTIVITY OF PF07248144 IN PARTICIPANTS WITH ADVANCED OR METASTATIC SOLID TUMORS | No dispute reported | 06/30/2026 | 1228709796 |
| Principal investigator 1 | Hoffmann-La Roche Limited | $4,853.64 | 12/10/2025 | Covered Recipient Teaching Hospital Langley Porter Psychiatric Hospital | Morpheus Breast Cancer | No dispute reported | 06/30/2026 | 1211547194 |
| Recipient | Novartis Pharmaceuticals Corporation | $617.57 | 12/10/2025 | Covered Recipient Physician | Research Publication/ Writing Support | No dispute reported | 06/30/2026 | 1190291186 |
| Principal investigator 1 | Gilead Sciences, Inc. | $117,311.00 | 12/09/2025 | Non-covered Recipient Entity JOHNS HOPKINS UNIVERSITY | IMMU132-2020-050 / TBCRC 047 Innovative Combination Immunotherapy for Metastatic Triple Negative Breast Cancer (TNBC): A multicenter, multi-arm Translational Breast Cancer Research Consortium study (TBCRC 047: InCITe) | No dispute reported | 06/30/2026 | 1229213608 |
| Recipient | PFIZER INC. | $940.00 | 12/09/2025 | Covered Recipient Physician | LADIRATUZUMAB VEDOTIN CLINICAL PUBLICATION PROGRAM | No dispute reported | 06/30/2026 | 1228727501 |
| Principal investigator 1 | PFIZER INC. | $34,174.42 | 11/26/2025 | Covered Recipient Teaching Hospital Langley Porter Psychiatric Hospital | AN INTERVENTIONAL OPENLABEL RANDOMIZED MULTICENTER PHASE 3 STUDY OF PF07220060 PLUS LETROZOLE COMPARED TO CDK46 INHIBITOR PLUS LETROZOLE IN PARTICIPANTS OVER 18 YEARS OF AGE WITH HORMONE RECEPTOR HRPOSITIVE HER2NEGATIVE ADVANCEDMETASTATIC BREAST CANCER WHO HAVE NOT RECEIVED ANY PRIOR SYSTEMIC ANTICANCER TREATMENT FOR ADVANCEDMETASTATIC DISEASE FOURLIGHT3 | No dispute reported | 06/30/2026 | 1228709958 |
| Recipient | PFIZER INC. | $3,200.00 | 11/24/2025 | Covered Recipient Physician | PALBOCICLIB CLINICAL PUBLICATION PROGRAM | No dispute reported | 06/30/2026 | 1228727545 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $118.72 | 11/12/2025 | Non-covered Recipient Entity THE REGENTS OF THE UNIVERSITY UCSF | A RANDOMIZED PHASE 3 DOUBLE-BLINDED STUDY COMPARING THE EFFICACY AND S | No dispute reported | 06/30/2026 | 1192114767 |
| Principal investigator 1 | Hoffmann-La Roche Limited | $2,426.82 | 11/12/2025 | Covered Recipient Teaching Hospital Langley Porter Psychiatric Hospital | Morpheus Breast Cancer | No dispute reported | 06/30/2026 | 1211547190 |
| Principal investigator 1 | PFIZER INC. | $3,265.77 | 11/01/2025 | Covered Recipient Teaching Hospital Langley Porter Psychiatric Hospital | A TREATMENT PROTOCOL FOR PARTICIPANTS CONTINUING FROM PFIZERSPONSORED PALBOCICLIB CLINICAL STUDIES | No dispute reported | 06/30/2026 | 1228709956 |
| Principal investigator 1 | Astellas Pharma Global Development | $1,970.22 | 10/30/2025 | Covered Recipient Teaching Hospital Langley Porter Psychiatric Hospital | An Open-label, Multicenter, Multicohort, Phase 2 Study to Evaluate Enfortumab Vedotin in Subjects With Previously Treated Locally Advanced or Metastatic Malignant Solid Tumors (EV-202) | No dispute reported | 06/30/2026 | 1234179776 |
| Principal investigator 1 | Astellas Pharma Global Development | $447.55 | 10/30/2025 | Covered Recipient Teaching Hospital Langley Porter Psychiatric Hospital | An Open-label, Multicenter, Multicohort, Phase 2 Study to Evaluate Enfortumab Vedotin in Subjects With Previously Treated Locally Advanced or Metastatic Malignant Solid Tumors (EV-202) | No dispute reported | 06/30/2026 | 1234179778 |
| Principal investigator 1 | Astellas Pharma Global Development | $1,860.00 | 10/30/2025 | Covered Recipient Teaching Hospital Langley Porter Psychiatric Hospital | An Open-label, Multicenter, Multicohort, Phase 2 Study to Evaluate Enfortumab Vedotin in Subjects With Previously Treated Locally Advanced or Metastatic Malignant Solid Tumors (EV-202) | No dispute reported | 06/30/2026 | 1234179780 |
| Principal investigator 1 | Astellas Pharma Global Development | $665.00 | 10/30/2025 | Covered Recipient Teaching Hospital Langley Porter Psychiatric Hospital | An Open-label, Multicenter, Multicohort, Phase 2 Study to Evaluate Enfortumab Vedotin in Subjects With Previously Treated Locally Advanced or Metastatic Malignant Solid Tumors (EV-202) | No dispute reported | 06/30/2026 | 1234179782 |
| Principal investigator 1 | Astellas Pharma Global Development | $2,660.00 | 10/30/2025 | Covered Recipient Teaching Hospital Langley Porter Psychiatric Hospital | An Open-label, Multicenter, Multicohort, Phase 2 Study to Evaluate Enfortumab Vedotin in Subjects With Previously Treated Locally Advanced or Metastatic Malignant Solid Tumors (EV-202) | No dispute reported | 06/30/2026 | 1234179784 |
| Principal investigator 1 | Astellas Pharma Global Development | $447.55 | 10/30/2025 | Covered Recipient Teaching Hospital Langley Porter Psychiatric Hospital | An Open-label, Multicenter, Multicohort, Phase 2 Study to Evaluate Enfortumab Vedotin in Subjects With Previously Treated Locally Advanced or Metastatic Malignant Solid Tumors (EV-202) | No dispute reported | 06/30/2026 | 1234179786 |
| Principal investigator 1 | Astellas Pharma Global Development | $731.50 | 10/30/2025 | Covered Recipient Teaching Hospital Langley Porter Psychiatric Hospital | An Open-label, Multicenter, Multicohort, Phase 2 Study to Evaluate Enfortumab Vedotin in Subjects With Previously Treated Locally Advanced or Metastatic Malignant Solid Tumors (EV-202) | No dispute reported | 06/30/2026 | 1234179788 |
| Principal investigator 1 | Astellas Pharma Global Development | $2,460.50 | 10/30/2025 | Covered Recipient Teaching Hospital Langley Porter Psychiatric Hospital | An Open-label, Multicenter, Multicohort, Phase 2 Study to Evaluate Enfortumab Vedotin in Subjects With Previously Treated Locally Advanced or Metastatic Malignant Solid Tumors (EV-202) | No dispute reported | 06/30/2026 | 1234179790 |
| Principal investigator 1 | Astellas Pharma Global Development | $9,318.11 | 10/30/2025 | Covered Recipient Teaching Hospital Langley Porter Psychiatric Hospital | An Open-label, Multicenter, Multicohort, Phase 2 Study to Evaluate Enfortumab Vedotin in Subjects With Previously Treated Locally Advanced or Metastatic Malignant Solid Tumors (EV-202) | No dispute reported | 06/30/2026 | 1234179792 |
| Principal investigator 1 | Astellas Pharma Global Development | $321.36 | 10/30/2025 | Covered Recipient Teaching Hospital Langley Porter Psychiatric Hospital | An Open-label, Multicenter, Multicohort, Phase 2 Study to Evaluate Enfortumab Vedotin in Subjects With Previously Treated Locally Advanced or Metastatic Malignant Solid Tumors (EV-202) | No dispute reported | 06/30/2026 | 1234179794 |
| Principal investigator 1 | Astellas Pharma Global Development | $744.79 | 10/30/2025 | Covered Recipient Teaching Hospital Langley Porter Psychiatric Hospital | An Open-label, Multicenter, Multicohort, Phase 2 Study to Evaluate Enfortumab Vedotin in Subjects With Previously Treated Locally Advanced or Metastatic Malignant Solid Tumors (EV-202) | No dispute reported | 06/30/2026 | 1234179796 |
| Principal investigator 1 | Astellas Pharma Global Development | $3,115.74 | 10/30/2025 | Covered Recipient Teaching Hospital Langley Porter Psychiatric Hospital | An Open-label, Multicenter, Multicohort, Phase 2 Study to Evaluate Enfortumab Vedotin in Subjects With Previously Treated Locally Advanced or Metastatic Malignant Solid Tumors (EV-202) | No dispute reported | 06/30/2026 | 1234179798 |
| Principal investigator 1 | Astellas Pharma Global Development | $2,660.00 | 10/30/2025 | Covered Recipient Teaching Hospital Langley Porter Psychiatric Hospital | An Open-label, Multicenter, Multicohort, Phase 2 Study to Evaluate Enfortumab Vedotin in Subjects With Previously Treated Locally Advanced or Metastatic Malignant Solid Tumors (EV-202) | No dispute reported | 06/30/2026 | 1234179800 |
| Recipient | F. Hoffmann-La Roche AG | $1,225.57 | 10/18/2025 | Covered Recipient Physician | Phase III study of giredestrant everolimus vs everolimus exemestane in ER HER2 locally adv or mBC | No dispute reported | 06/30/2026 | 1211536057 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $2,660.00 | 10/14/2025 | Non-covered Recipient Entity THE REGENTS OF THE UNIVERSITY UCSF | A RANDOMIZED PHASE 3 DOUBLE-BLINDED STUDY COMPARING THE EFFICACY AND S | No dispute reported | 06/30/2026 | 1192114755 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $2,460.00 | 10/14/2025 | Non-covered Recipient Entity THE REGENTS OF THE UNIVERSITY UCSF | A RANDOMIZED PHASE 3 DOUBLE-BLINDED STUDY COMPARING THE EFFICACY AND S | No dispute reported | 06/30/2026 | 1192114761 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $1,600.00 | 10/14/2025 | Non-covered Recipient Entity THE REGENTS OF THE UNIVERSITY UCSF | A RANDOMIZED PHASE 3 DOUBLE-BLINDED STUDY COMPARING THE EFFICACY AND S | No dispute reported | 06/30/2026 | 1192114774 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $665.00 | 10/14/2025 | Non-covered Recipient Entity THE REGENTS OF THE UNIVERSITY UCSF | A RANDOMIZED PHASE 3 DOUBLE-BLINDED STUDY COMPARING THE EFFICACY AND S | No dispute reported | 06/30/2026 | 1192114781 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $305.90 | 10/14/2025 | Non-covered Recipient Entity THE REGENTS OF THE UNIVERSITY UCSF | A RANDOMIZED PHASE 3 DOUBLE-BLINDED STUDY COMPARING THE EFFICACY AND S | No dispute reported | 06/30/2026 | 1192173736 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $1,330.00 | 10/14/2025 | Non-covered Recipient Entity THE REGENTS OF THE UNIVERSITY UCSF | A RANDOMIZED PHASE 3 DOUBLE-BLINDED STUDY COMPARING THE EFFICACY AND S | No dispute reported | 06/30/2026 | 1192173739 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $2,460.00 | 10/14/2025 | Non-covered Recipient Entity THE REGENTS OF THE UNIVERSITY UCSF | A RANDOMIZED PHASE 3 DOUBLE-BLINDED STUDY COMPARING THE EFFICACY AND S | No dispute reported | 06/30/2026 | 1192173744 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $1,330.00 | 10/14/2025 | Non-covered Recipient Entity THE REGENTS OF THE UNIVERSITY UCSF | A RANDOMIZED PHASE 3 DOUBLE-BLINDED STUDY COMPARING THE EFFICACY AND S | No dispute reported | 06/30/2026 | 1192173748 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $731.50 | 10/14/2025 | Non-covered Recipient Entity THE REGENTS OF THE UNIVERSITY UCSF | A RANDOMIZED PHASE 3 DOUBLE-BLINDED STUDY COMPARING THE EFFICACY AND S | No dispute reported | 06/30/2026 | 1192173751 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $4,256.00 | 10/14/2025 | Non-covered Recipient Entity THE REGENTS OF THE UNIVERSITY UCSF | A RANDOMIZED PHASE 3 DOUBLE-BLINDED STUDY COMPARING THE EFFICACY AND S | No dispute reported | 06/30/2026 | 1192173757 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $2,660.00 | 10/14/2025 | Non-covered Recipient Entity THE REGENTS OF THE UNIVERSITY UCSF | A RANDOMIZED PHASE 3 DOUBLE-BLINDED STUDY COMPARING THE EFFICACY AND S | No dispute reported | 06/30/2026 | 1192173761 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $339.00 | 10/14/2025 | Non-covered Recipient Entity THE REGENTS OF THE UNIVERSITY UCSF | A RANDOMIZED PHASE 3 DOUBLE-BLINDED STUDY COMPARING THE EFFICACY AND S | No dispute reported | 06/30/2026 | 1192173766 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $219.45 | 10/14/2025 | Non-covered Recipient Entity THE REGENTS OF THE UNIVERSITY UCSF | A RANDOMIZED PHASE 3 DOUBLE-BLINDED STUDY COMPARING THE EFFICACY AND S | No dispute reported | 06/30/2026 | 1192174717 |
| Principal investigator 1 | Hoffmann-La Roche Limited | $38,321.52 | 10/08/2025 | Covered Recipient Teaching Hospital Langley Porter Psychiatric Hospital | Morpheus Breast Cancer | No dispute reported | 06/30/2026 | 1211547186 |
| Principal investigator 1 | PFIZER INC. | $1,088.59 | 10/07/2025 | Covered Recipient Teaching Hospital Langley Porter Psychiatric Hospital | A TREATMENT PROTOCOL FOR PARTICIPANTS CONTINUING FROM PFIZERSPONSORED PALBOCICLIB CLINICAL STUDIES | No dispute reported | 06/30/2026 | 1228709866 |
| Principal investigator 1 | PFIZER INC. | $54.70 | 10/02/2025 | Covered Recipient Teaching Hospital Langley Porter Psychiatric Hospital | PALLASPALBOCICLIB COLLABORATIVE ADJUVANT STUDYA RANDOMIZED PHASE III TRIAL OF PALBOCICLIB WITH STANDARD ADJUVANT ENDOCRINE THERAPY VERSUS STANDARD ADJUVANT ENDOCRINE THERAPY ALONE FOR HR OR HER2 EARLY BREAST CANCER WI203696 | No dispute reported | 06/30/2026 | 1228709478 |
| Principal investigator 1 | PFIZER INC. | $54.70 | 10/02/2025 | Covered Recipient Teaching Hospital Langley Porter Psychiatric Hospital | PALLASPALBOCICLIB COLLABORATIVE ADJUVANT STUDYA RANDOMIZED PHASE III TRIAL OF PALBOCICLIB WITH STANDARD ADJUVANT ENDOCRINE THERAPY VERSUS STANDARD ADJUVANT ENDOCRINE THERAPY ALONE FOR HR OR HER2 EARLY BREAST CANCER WI203696 | No dispute reported | 06/30/2026 | 1228709640 |
| Principal investigator 1 | PFIZER INC. | $500.00 | 10/02/2025 | Covered Recipient Teaching Hospital Langley Porter Psychiatric Hospital | PALLASPALBOCICLIB COLLABORATIVE ADJUVANT STUDYA RANDOMIZED PHASE III TRIAL OF PALBOCICLIB WITH STANDARD ADJUVANT ENDOCRINE THERAPY VERSUS STANDARD ADJUVANT ENDOCRINE THERAPY ALONE FOR HR OR HER2 EARLY BREAST CANCER WI203696 | No dispute reported | 06/30/2026 | 1228709798 |
| Principal investigator 1 | Astellas Pharma Global Development | $7,980.00 | 09/25/2025 | Covered Recipient Teaching Hospital Langley Porter Psychiatric Hospital | An Open-label, Multicenter, Multicohort, Phase 2 Study to Evaluate Enfortumab Vedotin in Subjects With Previously Treated Locally Advanced or Metastatic Malignant Solid Tumors (EV-202) | No dispute reported | 06/30/2026 | 1234179770 |
| Principal investigator 1 | Astellas Pharma Global Development | $5,320.00 | 09/25/2025 | Covered Recipient Teaching Hospital Langley Porter Psychiatric Hospital | An Open-label, Multicenter, Multicohort, Phase 2 Study to Evaluate Enfortumab Vedotin in Subjects With Previously Treated Locally Advanced or Metastatic Malignant Solid Tumors (EV-202) | No dispute reported | 06/30/2026 | 1234179772 |
| Principal investigator 1 | Astellas Pharma Global Development | $4,921.00 | 09/25/2025 | Covered Recipient Teaching Hospital Langley Porter Psychiatric Hospital | An Open-label, Multicenter, Multicohort, Phase 2 Study to Evaluate Enfortumab Vedotin in Subjects With Previously Treated Locally Advanced or Metastatic Malignant Solid Tumors (EV-202) | No dispute reported | 06/30/2026 | 1234179774 |
| Principal investigator 1 | Hoffmann-La Roche Limited | $2,426.82 | 09/17/2025 | Covered Recipient Teaching Hospital Langley Porter Psychiatric Hospital | Morpheus Breast Cancer | No dispute reported | 06/30/2026 | 1211547183 |
| Principal investigator 1 | PFIZER INC. | $7,620.13 | 08/30/2025 | Covered Recipient Teaching Hospital Langley Porter Psychiatric Hospital | A TREATMENT PROTOCOL FOR PARTICIPANTS CONTINUING FROM PFIZERSPONSORED PALBOCICLIB CLINICAL STUDIES | No dispute reported | 06/30/2026 | 1228710892 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $325.20 | 08/25/2025 | Covered Recipient Teaching Hospital Langley Porter Psychiatric Hospital | DS8201-A-U303 | No dispute reported | 06/30/2026 | 1223347412 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $542.00 | 08/25/2025 | Covered Recipient Teaching Hospital Langley Porter Psychiatric Hospital | DS8201-A-U303 | No dispute reported | 06/30/2026 | 1223347414 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $542.00 | 08/25/2025 | Covered Recipient Teaching Hospital Langley Porter Psychiatric Hospital | DS8201-A-U303 | No dispute reported | 06/30/2026 | 1223347416 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $542.00 | 08/25/2025 | Covered Recipient Teaching Hospital Langley Porter Psychiatric Hospital | DS8201-A-U303 | No dispute reported | 06/30/2026 | 1223347418 |
| Principal investigator 1 | Hoffmann-La Roche Limited | $7,823.92 | 08/13/2025 | Covered Recipient Teaching Hospital Langley Porter Psychiatric Hospital | Morpheus Breast Cancer | No dispute reported | 06/30/2026 | 1211547179 |
| Principal investigator 1 | PFIZER INC. | $5,442.95 | 07/24/2025 | Covered Recipient Teaching Hospital Langley Porter Psychiatric Hospital | A TREATMENT PROTOCOL FOR PARTICIPANTS CONTINUING FROM PFIZERSPONSORED PALBOCICLIB CLINICAL STUDIES | No dispute reported | 06/30/2026 | 1228709484 |
| Principal investigator 1 | Hoffmann-La Roche Limited | $2,426.82 | 07/11/2025 | Covered Recipient Teaching Hospital Langley Porter Psychiatric Hospital | Morpheus Breast Cancer | No dispute reported | 06/30/2026 | 1211547176 |
| Principal investigator 1 | PFIZER INC. | $3,265.77 | 07/10/2025 | Covered Recipient Teaching Hospital Langley Porter Psychiatric Hospital | A TREATMENT PROTOCOL FOR PARTICIPANTS CONTINUING FROM PFIZERSPONSORED PALBOCICLIB CLINICAL STUDIES | No dispute reported | 06/30/2026 | 1228709486 |
| Principal investigator 1 | Janssen Research & Development, LLC | $24,077.70 | 07/09/2025 | Covered Recipient Teaching Hospital Uc Davis Medical Center | A Global, Phase 2 Study of ARX788 in HER2-positive Metastatic Breast Cancer Patients Who Were Previously Treated With T-DXd | No dispute reported | 06/30/2026 | 1175176628 |
| Principal investigator 1 | Janssen Research & Development, LLC | $31,977.50 | 07/09/2025 | Covered Recipient Teaching Hospital Uc Davis Medical Center | A Global, Phase 2 Study of ARX788 in HER2-positive Metastatic Breast Cancer Patients Who Were Previously Treated With T-DXd | No dispute reported | 06/30/2026 | 1175176988 |
| Recipient | PFIZER INC. | $330.00 | 07/08/2025 | Covered Recipient Physician | PALBOCICLIB CLINICAL PUBLICATION PROGRAM | No dispute reported | 06/30/2026 | 1228722860 |
| Principal investigator 1 | PFIZER INC. | $103,507.60 | 06/26/2025 | Covered Recipient Teaching Hospital Langley Porter Psychiatric Hospital | AN INTERVENTIONAL OPENLABEL RANDOMIZED MULTICENTER PHASE 3 STUDY OF PF07220060 PLUS FULVESTRANT COMPARED TO INVESTIGATORS CHOICE OF THERAPY IN PARTICIPANTS OVER 18 YEARS OF AGE WITH HORMONE RECEPTORPOSITIVE HER2NEGATIVE ADVANCEDMETASTATIC BREAST CANCER WHOSE DISEASE PROGRESSED AFTER PRIOR CDK 46 INHIBITOR BASED THERAPY | No dispute reported | 06/30/2026 | 1228709482 |
| Principal investigator 1 | PFIZER INC. | $500.00 | 06/23/2025 | Covered Recipient Teaching Hospital Langley Porter Psychiatric Hospital | PALLASPALBOCICLIB COLLABORATIVE ADJUVANT STUDYA RANDOMIZED PHASE III TRIAL OF PALBOCICLIB WITH STANDARD ADJUVANT ENDOCRINE THERAPY VERSUS STANDARD ADJUVANT ENDOCRINE THERAPY ALONE FOR HR OR HER2 EARLY BREAST CANCER WI203696 | No dispute reported | 06/30/2026 | 1228709566 |
| Principal investigator 1 | PFIZER INC. | $500.00 | 06/23/2025 | Covered Recipient Teaching Hospital Langley Porter Psychiatric Hospital | PALLASPALBOCICLIB COLLABORATIVE ADJUVANT STUDYA RANDOMIZED PHASE III TRIAL OF PALBOCICLIB WITH STANDARD ADJUVANT ENDOCRINE THERAPY VERSUS STANDARD ADJUVANT ENDOCRINE THERAPY ALONE FOR HR OR HER2 EARLY BREAST CANCER WI203696 | No dispute reported | 06/30/2026 | 1228709568 |
| Principal investigator 1 | PFIZER INC. | $500.00 | 06/23/2025 | Covered Recipient Teaching Hospital Langley Porter Psychiatric Hospital | PALLASPALBOCICLIB COLLABORATIVE ADJUVANT STUDYA RANDOMIZED PHASE III TRIAL OF PALBOCICLIB WITH STANDARD ADJUVANT ENDOCRINE THERAPY VERSUS STANDARD ADJUVANT ENDOCRINE THERAPY ALONE FOR HR OR HER2 EARLY BREAST CANCER WI203696 | No dispute reported | 06/30/2026 | 1228709570 |
| Principal investigator 1 | PFIZER INC. | $500.00 | 06/23/2025 | Covered Recipient Teaching Hospital Langley Porter Psychiatric Hospital | PALLASPALBOCICLIB COLLABORATIVE ADJUVANT STUDYA RANDOMIZED PHASE III TRIAL OF PALBOCICLIB WITH STANDARD ADJUVANT ENDOCRINE THERAPY VERSUS STANDARD ADJUVANT ENDOCRINE THERAPY ALONE FOR HR OR HER2 EARLY BREAST CANCER WI203696 | No dispute reported | 06/30/2026 | 1228709572 |
| Principal investigator 1 | PFIZER INC. | $500.00 | 06/23/2025 | Covered Recipient Teaching Hospital Langley Porter Psychiatric Hospital | PALLASPALBOCICLIB COLLABORATIVE ADJUVANT STUDYA RANDOMIZED PHASE III TRIAL OF PALBOCICLIB WITH STANDARD ADJUVANT ENDOCRINE THERAPY VERSUS STANDARD ADJUVANT ENDOCRINE THERAPY ALONE FOR HR OR HER2 EARLY BREAST CANCER WI203696 | No dispute reported | 06/30/2026 | 1228709574 |
| Principal investigator 1 | PFIZER INC. | $500.00 | 06/23/2025 | Covered Recipient Teaching Hospital Langley Porter Psychiatric Hospital | PALLASPALBOCICLIB COLLABORATIVE ADJUVANT STUDYA RANDOMIZED PHASE III TRIAL OF PALBOCICLIB WITH STANDARD ADJUVANT ENDOCRINE THERAPY VERSUS STANDARD ADJUVANT ENDOCRINE THERAPY ALONE FOR HR OR HER2 EARLY BREAST CANCER WI203696 | No dispute reported | 06/30/2026 | 1228709576 |
| Principal investigator 1 | PFIZER INC. | $500.00 | 06/23/2025 | Covered Recipient Teaching Hospital Langley Porter Psychiatric Hospital | PALLASPALBOCICLIB COLLABORATIVE ADJUVANT STUDYA RANDOMIZED PHASE III TRIAL OF PALBOCICLIB WITH STANDARD ADJUVANT ENDOCRINE THERAPY VERSUS STANDARD ADJUVANT ENDOCRINE THERAPY ALONE FOR HR OR HER2 EARLY BREAST CANCER WI203696 | No dispute reported | 06/30/2026 | 1228710800 |
| Principal investigator 1 | PFIZER INC. | $500.00 | 06/23/2025 | Covered Recipient Teaching Hospital Langley Porter Psychiatric Hospital | PALLASPALBOCICLIB COLLABORATIVE ADJUVANT STUDYA RANDOMIZED PHASE III TRIAL OF PALBOCICLIB WITH STANDARD ADJUVANT ENDOCRINE THERAPY VERSUS STANDARD ADJUVANT ENDOCRINE THERAPY ALONE FOR HR OR HER2 EARLY BREAST CANCER WI203696 | No dispute reported | 06/30/2026 | 1228710802 |
| Principal investigator 1 | Hoffmann-La Roche Limited | $4,853.64 | 06/18/2025 | Covered Recipient Teaching Hospital Langley Porter Psychiatric Hospital | Morpheus Breast Cancer | No dispute reported | 06/30/2026 | 1211547172 |
| Principal investigator 1 | Genentech, Inc. | $56,430.38 | 06/17/2025 | Covered Recipient Teaching Hospital Langley Porter Psychiatric Hospital | Phase III study of giredestrant everolimus vs everolimus exemestane in ER HER2 locally adv or mBC | No dispute reported | 06/30/2026 | 1211548087 |
| Recipient | PFIZER INC. | $3,200.00 | 06/04/2025 | Covered Recipient Physician | PALBOCICLIB CLINICAL PUBLICATION PROGRAM | No dispute reported | 06/30/2026 | 1228760377 |
| Recipient | PFIZER INC. | $3,200.00 | 06/04/2025 | Covered Recipient Physician | PALBOCICLIB CLINICAL PUBLICATION PROGRAM | No dispute reported | 06/30/2026 | 1228771116 |
| Principal investigator 1 | PFIZER INC. | $54.70 | 05/30/2025 | Covered Recipient Teaching Hospital Langley Porter Psychiatric Hospital | PALLASPALBOCICLIB COLLABORATIVE ADJUVANT STUDYA RANDOMIZED PHASE III TRIAL OF PALBOCICLIB WITH STANDARD ADJUVANT ENDOCRINE THERAPY VERSUS STANDARD ADJUVANT ENDOCRINE THERAPY ALONE FOR HR OR HER2 EARLY BREAST CANCER WI203696 | No dispute reported | 06/30/2026 | 1228709480 |
| Recipient | PFIZER INC. | $940.00 | 05/30/2025 | Covered Recipient Physician | ELRANATAMAB CLINICAL PUBLICATION PROGRAM | No dispute reported | 06/30/2026 | 1228752913 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $1,625.40 | 05/27/2025 | Covered Recipient Teaching Hospital Langley Porter Psychiatric Hospital | DS8201-A-U303 | No dispute reported | 06/30/2026 | 1223347410 |
| Principal investigator 1 | Merck Sharp & Dohme LLC | $13,004.28 | 05/26/2025 | Covered Recipient Teaching Hospital Langley Porter Psychiatric Hospital | A Randomized, Double-Blind, Phase III Study of Pembrolizumab MK-3475 plus Chemotherapy vs Placebo plus Chemotherapy for Previously Untreated Locally Recurrent Inoperable or Metastatic Triple Negative Breast Cancer - KEYNOTE-355 | No dispute reported | 06/30/2026 | 1232925863 |
| Principal investigator 1 | PFIZER INC. | $1,088.59 | 05/22/2025 | Covered Recipient Teaching Hospital Langley Porter Psychiatric Hospital | A TREATMENT PROTOCOL FOR PARTICIPANTS CONTINUING FROM PFIZERSPONSORED PALBOCICLIB CLINICAL STUDIES | No dispute reported | 06/30/2026 | 1228709648 |
| Principal investigator 1 | Hoffmann-La Roche Limited | $16,565.89 | 05/21/2025 | Covered Recipient Teaching Hospital Langley Porter Psychiatric Hospital | Morpheus Breast Cancer | No dispute reported | 06/30/2026 | 1211547163 |
| Recipient | PFIZER INC. | $940.00 | 05/15/2025 | Covered Recipient Physician | PALBOCICLIB CLINICAL PUBLICATION PROGRAM | No dispute reported | 06/30/2026 | 1228770954 |
| Principal investigator 1 | Merck Sharp & Dohme LLC | $48,198.82 | 05/14/2025 | Covered Recipient Teaching Hospital Langley Porter Psychiatric Hospital | An Open-label, Randomized, Phase 2,3 Study of Olaparib Plus Pembrolizumab Versus Chemotherapy Plus Pembrolizumab After Induction of Clinical Benefit With First-line Chemotherapy Plus Pembrolizumab in Participants With Locally Recurrent Inoperable or Metas | No dispute reported | 06/30/2026 | 1232917761 |
| Recipient | Novartis Pharmaceuticals Corporation | $3,844.90 | 05/13/2025 | Covered Recipient Physician | China IITvsUS Flatiron AB | No dispute reported | 06/30/2026 | 1190292416 |
| Recipient | PFIZER INC. | $330.00 | 05/13/2025 | Covered Recipient Physician | PALBOCICLIB CLINICAL PUBLICATION PROGRAM | No dispute reported | 06/30/2026 | 1228771493 |
| Principal investigator 1 | Hoffmann-La Roche Limited | $13,991.80 | 04/30/2025 | Covered Recipient Teaching Hospital Langley Porter Psychiatric Hospital | Morpheus Breast Cancer | No dispute reported | 06/30/2026 | 1211547167 |
| Principal investigator 1 | Genentech, Inc. | $14,542.00 | 04/29/2025 | Covered Recipient Teaching Hospital Langley Porter Psychiatric Hospital | PD1 LAG3 Chemo Value over Pembro Chemo 1L PDL1 mTNBC | No dispute reported | 06/30/2026 | 1211548104 |
| Recipient | PFIZER INC. | $780.00 | 04/25/2025 | Covered Recipient Physician | PALBOCICLIB CLINICAL PUBLICATION PROGRAM | No dispute reported | 06/30/2026 | 1228769062 |
| Principal investigator 1 | PFIZER INC. | $2,177.18 | 04/23/2025 | Covered Recipient Teaching Hospital Langley Porter Psychiatric Hospital | A TREATMENT PROTOCOL FOR PARTICIPANTS CONTINUING FROM PFIZERSPONSORED PALBOCICLIB CLINICAL STUDIES | No dispute reported | 06/30/2026 | 1228709646 |
| Recipient | Novartis Pharma AG | $1,445.70 | 04/14/2025 | Covered Recipient Physician | CBYL719C2301 | No dispute reported | 06/30/2026 | 1248109291 |
| Principal investigator 1 | Astellas Pharma Global Development | $416.06 | 04/08/2025 | Covered Recipient Teaching Hospital Langley Porter Psychiatric Hospital | An Open-label, Multicenter, Multicohort, Phase 2 Study to Evaluate Enfortumab Vedotin in Subjects With Previously Treated Locally Advanced or Metastatic Malignant Solid Tumors (EV-202) | No dispute reported | 06/30/2026 | 1234179718 |
| Principal investigator 1 | Astellas Pharma Global Development | $416.06 | 04/08/2025 | Covered Recipient Teaching Hospital Langley Porter Psychiatric Hospital | An Open-label, Multicenter, Multicohort, Phase 2 Study to Evaluate Enfortumab Vedotin in Subjects With Previously Treated Locally Advanced or Metastatic Malignant Solid Tumors (EV-202) | No dispute reported | 06/30/2026 | 1234179720 |
| Principal investigator 1 | Astellas Pharma Global Development | $416.06 | 04/08/2025 | Covered Recipient Teaching Hospital Langley Porter Psychiatric Hospital | An Open-label, Multicenter, Multicohort, Phase 2 Study to Evaluate Enfortumab Vedotin in Subjects With Previously Treated Locally Advanced or Metastatic Malignant Solid Tumors (EV-202) | No dispute reported | 06/30/2026 | 1234179722 |
| Principal investigator 1 | Astellas Pharma Global Development | $416.06 | 04/08/2025 | Covered Recipient Teaching Hospital Langley Porter Psychiatric Hospital | An Open-label, Multicenter, Multicohort, Phase 2 Study to Evaluate Enfortumab Vedotin in Subjects With Previously Treated Locally Advanced or Metastatic Malignant Solid Tumors (EV-202) | No dispute reported | 06/30/2026 | 1234179724 |
| Principal investigator 1 | Astellas Pharma Global Development | $416.06 | 04/08/2025 | Covered Recipient Teaching Hospital Langley Porter Psychiatric Hospital | An Open-label, Multicenter, Multicohort, Phase 2 Study to Evaluate Enfortumab Vedotin in Subjects With Previously Treated Locally Advanced or Metastatic Malignant Solid Tumors (EV-202) | No dispute reported | 06/30/2026 | 1234179726 |
| Principal investigator 1 | Astellas Pharma Global Development | $416.06 | 04/08/2025 | Covered Recipient Teaching Hospital Langley Porter Psychiatric Hospital | An Open-label, Multicenter, Multicohort, Phase 2 Study to Evaluate Enfortumab Vedotin in Subjects With Previously Treated Locally Advanced or Metastatic Malignant Solid Tumors (EV-202) | No dispute reported | 06/30/2026 | 1234179728 |
| Principal investigator 1 | Astellas Pharma Global Development | $416.06 | 04/08/2025 | Covered Recipient Teaching Hospital Langley Porter Psychiatric Hospital | An Open-label, Multicenter, Multicohort, Phase 2 Study to Evaluate Enfortumab Vedotin in Subjects With Previously Treated Locally Advanced or Metastatic Malignant Solid Tumors (EV-202) | No dispute reported | 06/30/2026 | 1234179730 |
| Principal investigator 1 | Astellas Pharma Global Development | $416.06 | 04/08/2025 | Covered Recipient Teaching Hospital Langley Porter Psychiatric Hospital | An Open-label, Multicenter, Multicohort, Phase 2 Study to Evaluate Enfortumab Vedotin in Subjects With Previously Treated Locally Advanced or Metastatic Malignant Solid Tumors (EV-202) | No dispute reported | 06/30/2026 | 1234179732 |
| Principal investigator 1 | Astellas Pharma Global Development | $416.06 | 04/08/2025 | Covered Recipient Teaching Hospital Langley Porter Psychiatric Hospital | An Open-label, Multicenter, Multicohort, Phase 2 Study to Evaluate Enfortumab Vedotin in Subjects With Previously Treated Locally Advanced or Metastatic Malignant Solid Tumors (EV-202) | No dispute reported | 06/30/2026 | 1234179734 |
| Principal investigator 1 | Astellas Pharma Global Development | $416.06 | 04/08/2025 | Covered Recipient Teaching Hospital Langley Porter Psychiatric Hospital | An Open-label, Multicenter, Multicohort, Phase 2 Study to Evaluate Enfortumab Vedotin in Subjects With Previously Treated Locally Advanced or Metastatic Malignant Solid Tumors (EV-202) | No dispute reported | 06/30/2026 | 1234179736 |
| Principal investigator 1 | Astellas Pharma Global Development | $416.06 | 04/08/2025 | Covered Recipient Teaching Hospital Langley Porter Psychiatric Hospital | An Open-label, Multicenter, Multicohort, Phase 2 Study to Evaluate Enfortumab Vedotin in Subjects With Previously Treated Locally Advanced or Metastatic Malignant Solid Tumors (EV-202) | No dispute reported | 06/30/2026 | 1234179738 |
| Principal investigator 1 | Astellas Pharma Global Development | $416.06 | 04/08/2025 | Covered Recipient Teaching Hospital Langley Porter Psychiatric Hospital | An Open-label, Multicenter, Multicohort, Phase 2 Study to Evaluate Enfortumab Vedotin in Subjects With Previously Treated Locally Advanced or Metastatic Malignant Solid Tumors (EV-202) | No dispute reported | 06/30/2026 | 1234179740 |
| Principal investigator 1 | Astellas Pharma Global Development | $416.06 | 04/08/2025 | Covered Recipient Teaching Hospital Langley Porter Psychiatric Hospital | An Open-label, Multicenter, Multicohort, Phase 2 Study to Evaluate Enfortumab Vedotin in Subjects With Previously Treated Locally Advanced or Metastatic Malignant Solid Tumors (EV-202) | No dispute reported | 06/30/2026 | 1234179742 |
| Principal investigator 1 | Astellas Pharma Global Development | $416.06 | 04/08/2025 | Covered Recipient Teaching Hospital Langley Porter Psychiatric Hospital | An Open-label, Multicenter, Multicohort, Phase 2 Study to Evaluate Enfortumab Vedotin in Subjects With Previously Treated Locally Advanced or Metastatic Malignant Solid Tumors (EV-202) | No dispute reported | 06/30/2026 | 1234179744 |
| Principal investigator 1 | Astellas Pharma Global Development | $416.06 | 04/08/2025 | Covered Recipient Teaching Hospital Langley Porter Psychiatric Hospital | An Open-label, Multicenter, Multicohort, Phase 2 Study to Evaluate Enfortumab Vedotin in Subjects With Previously Treated Locally Advanced or Metastatic Malignant Solid Tumors (EV-202) | No dispute reported | 06/30/2026 | 1234179746 |
| Principal investigator 1 | Astellas Pharma Global Development | $416.06 | 04/08/2025 | Covered Recipient Teaching Hospital Langley Porter Psychiatric Hospital | An Open-label, Multicenter, Multicohort, Phase 2 Study to Evaluate Enfortumab Vedotin in Subjects With Previously Treated Locally Advanced or Metastatic Malignant Solid Tumors (EV-202) | No dispute reported | 06/30/2026 | 1234179748 |
| Principal investigator 1 | Astellas Pharma Global Development | $416.06 | 04/08/2025 | Covered Recipient Teaching Hospital Langley Porter Psychiatric Hospital | An Open-label, Multicenter, Multicohort, Phase 2 Study to Evaluate Enfortumab Vedotin in Subjects With Previously Treated Locally Advanced or Metastatic Malignant Solid Tumors (EV-202) | No dispute reported | 06/30/2026 | 1234179750 |
| Principal investigator 1 | Astellas Pharma Global Development | $416.06 | 04/08/2025 | Covered Recipient Teaching Hospital Langley Porter Psychiatric Hospital | An Open-label, Multicenter, Multicohort, Phase 2 Study to Evaluate Enfortumab Vedotin in Subjects With Previously Treated Locally Advanced or Metastatic Malignant Solid Tumors (EV-202) | No dispute reported | 06/30/2026 | 1234179752 |
| Principal investigator 1 | Astellas Pharma Global Development | $416.06 | 04/08/2025 | Covered Recipient Teaching Hospital Langley Porter Psychiatric Hospital | An Open-label, Multicenter, Multicohort, Phase 2 Study to Evaluate Enfortumab Vedotin in Subjects With Previously Treated Locally Advanced or Metastatic Malignant Solid Tumors (EV-202) | No dispute reported | 06/30/2026 | 1234179754 |
| Principal investigator 1 | Astellas Pharma Global Development | $416.06 | 04/08/2025 | Covered Recipient Teaching Hospital Langley Porter Psychiatric Hospital | An Open-label, Multicenter, Multicohort, Phase 2 Study to Evaluate Enfortumab Vedotin in Subjects With Previously Treated Locally Advanced or Metastatic Malignant Solid Tumors (EV-202) | No dispute reported | 06/30/2026 | 1234179756 |
| Principal investigator 1 | Astellas Pharma Global Development | $416.06 | 04/08/2025 | Covered Recipient Teaching Hospital Langley Porter Psychiatric Hospital | An Open-label, Multicenter, Multicohort, Phase 2 Study to Evaluate Enfortumab Vedotin in Subjects With Previously Treated Locally Advanced or Metastatic Malignant Solid Tumors (EV-202) | No dispute reported | 06/30/2026 | 1234179758 |
| Principal investigator 1 | Astellas Pharma Global Development | $416.06 | 04/08/2025 | Covered Recipient Teaching Hospital Langley Porter Psychiatric Hospital | An Open-label, Multicenter, Multicohort, Phase 2 Study to Evaluate Enfortumab Vedotin in Subjects With Previously Treated Locally Advanced or Metastatic Malignant Solid Tumors (EV-202) | No dispute reported | 06/30/2026 | 1234179760 |
| Principal investigator 1 | Astellas Pharma Global Development | $416.06 | 04/08/2025 | Covered Recipient Teaching Hospital Langley Porter Psychiatric Hospital | An Open-label, Multicenter, Multicohort, Phase 2 Study to Evaluate Enfortumab Vedotin in Subjects With Previously Treated Locally Advanced or Metastatic Malignant Solid Tumors (EV-202) | No dispute reported | 06/30/2026 | 1234179762 |
| Principal investigator 1 | Astellas Pharma Global Development | $416.06 | 04/08/2025 | Covered Recipient Teaching Hospital Langley Porter Psychiatric Hospital | An Open-label, Multicenter, Multicohort, Phase 2 Study to Evaluate Enfortumab Vedotin in Subjects With Previously Treated Locally Advanced or Metastatic Malignant Solid Tumors (EV-202) | No dispute reported | 06/30/2026 | 1234179764 |
| Principal investigator 1 | Astellas Pharma Global Development | $416.06 | 04/08/2025 | Covered Recipient Teaching Hospital Langley Porter Psychiatric Hospital | An Open-label, Multicenter, Multicohort, Phase 2 Study to Evaluate Enfortumab Vedotin in Subjects With Previously Treated Locally Advanced or Metastatic Malignant Solid Tumors (EV-202) | No dispute reported | 06/30/2026 | 1234179766 |
| Principal investigator 1 | Astellas Pharma Global Development | $416.06 | 04/08/2025 | Covered Recipient Teaching Hospital Langley Porter Psychiatric Hospital | An Open-label, Multicenter, Multicohort, Phase 2 Study to Evaluate Enfortumab Vedotin in Subjects With Previously Treated Locally Advanced or Metastatic Malignant Solid Tumors (EV-202) | No dispute reported | 06/30/2026 | 1234179768 |
| Recipient | PFIZER INC. | $3,200.00 | 04/07/2025 | Covered Recipient Physician | PALBOCICLIB CLINICAL PUBLICATION PROGRAM | No dispute reported | 06/30/2026 | 1228761810 |
| Principal investigator 1 | PFIZER INC. | $1,088.59 | 04/04/2025 | Covered Recipient Teaching Hospital Langley Porter Psychiatric Hospital | A TREATMENT PROTOCOL FOR PARTICIPANTS CONTINUING FROM PFIZERSPONSORED PALBOCICLIB CLINICAL STUDIES | No dispute reported | 06/30/2026 | 1228709644 |
| Principal investigator 1 | AstraZeneca Pharmaceuticals LP | $22,507.42 | 04/02/2025 | Covered Recipient Teaching Hospital Langley Porter Psychiatric Hospital | A PHASE 3, OPEN-LABEL, RANDOMIZED STUDY OF DATO-DXD VERSUS INVESTIGATORS CHOICE OF CHEMOTHERAPY IN PARTICIPANTS WITH INOPERABLE OR METASTATIC HORMONE RECEPTOR POSITIVE, HER2 NEGATIVE BREAST CANCER WHO HAVE BEEN TREATED WITH ONE OR TWO PRIOR LINES OF SYSTEMIC CHEMOTHERAPY | No dispute reported | 06/30/2026 | 1185544153 |
| Principal investigator 1 | Hoffmann-La Roche Limited | $11,021.52 | 03/19/2025 | Covered Recipient Teaching Hospital Langley Porter Psychiatric Hospital | Morpheus Breast Cancer | No dispute reported | 06/30/2026 | 1211547148 |
| Principal investigator 1 | PFIZER INC. | $54.70 | 03/12/2025 | Covered Recipient Teaching Hospital Langley Porter Psychiatric Hospital | PALLASPALBOCICLIB COLLABORATIVE ADJUVANT STUDYA RANDOMIZED PHASE III TRIAL OF PALBOCICLIB WITH STANDARD ADJUVANT ENDOCRINE THERAPY VERSUS STANDARD ADJUVANT ENDOCRINE THERAPY ALONE FOR HR OR HER2 EARLY BREAST CANCER WI203696 | No dispute reported | 06/30/2026 | 1228710804 |
| Principal investigator 1 | PFIZER INC. | $4,354.36 | 02/21/2025 | Covered Recipient Teaching Hospital Langley Porter Psychiatric Hospital | A TREATMENT PROTOCOL FOR PARTICIPANTS CONTINUING FROM PFIZERSPONSORED PALBOCICLIB CLINICAL STUDIES | No dispute reported | 06/30/2026 | 1228709864 |
| Principal investigator 1 | Hoffmann-La Roche Limited | $8,804.14 | 02/19/2025 | Covered Recipient Teaching Hospital Langley Porter Psychiatric Hospital | Morpheus Breast Cancer | No dispute reported | 06/30/2026 | 1211547152 |
| Principal investigator 1 | Hoffmann-La Roche Limited | $12,335.76 | 02/19/2025 | Covered Recipient Teaching Hospital Langley Porter Psychiatric Hospital | Morpheus Breast Cancer | No dispute reported | 06/30/2026 | 1211547159 |
| Principal investigator 1 | Eli Lilly and Company | $587.95 | 02/10/2025 | Covered Recipient Teaching Hospital LANGLEY PORTER PSYCHIATRIC HOSPITAL | EMBER-4: A RANDOMIZED, OPEN-LABEL, PHASE 3 STUDY OF ADJUVANT IMLUNESTRANT VS STANDARD ADJUVANT ENDOCRINE THERAPY IN PATIENTS WHO HAVE PREVIOUSLY RECEIVED 2 TO 5 YEARS OF ADJUVANT ENDOCRINE THERAPY FOR ER+, HER2- EARLY BREAST CANCER WITH AN INCREASED RISK OF RECURRENCE | No dispute reported | 06/30/2026 | 1187874547 |
| Principal investigator 1 | PFIZER INC. | $482,279.10 | 02/10/2025 | Non-covered Recipient Entity Johns Hopkins University | IMMUNOTHERAPY COMBINATION STRATEGIES TO TREAT TRIPLE NEGATIVE BREAST CANCER TNBCA MULTICENTER MULTIARM TRANSLATIONAL BREAST CANCER RESEARCH CONSORTIUM TBCRC STUDY | No dispute reported | 06/30/2026 | 1228752718 |
| Recipient | PFIZER INC. | $330.00 | 02/10/2025 | Covered Recipient Physician | PALBOCICLIB CLINICAL PUBLICATION PROGRAM | No dispute reported | 06/30/2026 | 1228768542 |
| Principal investigator 1 | Eli Lilly and Company | $2,816.76 | 02/06/2025 | Covered Recipient Teaching Hospital LANGLEY PORTER PSYCHIATRIC HOSPITAL | A STUDY OF LOXO-783 ADMINISTERED AS MONOTHERAPY AND IN COMBINATION WITH ANTICANCER THERAPIES FOR PATIENTS WITH ADVANCED BREAST CANCER AND OTHER SOLID TUMORS WITH A PIK3CA H1047R MUTATION | No dispute reported | 06/30/2026 | 1187872317 |
| Principal investigator 1 | PFIZER INC. | $82.50 | 02/04/2025 | Non-covered Recipient Entity UCSF Medical Centerat Mission Bay | A TREATMENT PROTOCOL FOR PARTICIPANTS CONTINUING FROM PFIZERSPONSORED PALBOCICLIB CLINICAL STUDIES | No dispute reported | 06/30/2026 | 1228769669 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $65,776.15 | 01/30/2025 | Covered Recipient Teaching Hospital Langley Porter Psychiatric Hospital | DS8201-U-106 | No dispute reported | 06/30/2026 | 1223347420 |
| Principal investigator 1 | Novartis Pharmaceuticals Corporation | $18,192.94 | 01/30/2025 | Non-covered Recipient Entity UNIVERSITY OF CALIFORNIA SAN FRANCISCO | Ribociclib Standard Endocrine therapy in patients with HR HER2 Early BC at High amp Intermediate Risk for Recurrence | No dispute reported | 06/30/2026 | 1190305697 |
| Principal investigator 1 | PFIZER INC. | $500.00 | 01/30/2025 | Covered Recipient Teaching Hospital Langley Porter Psychiatric Hospital | PALLASPALBOCICLIB COLLABORATIVE ADJUVANT STUDYA RANDOMIZED PHASE III TRIAL OF PALBOCICLIB WITH STANDARD ADJUVANT ENDOCRINE THERAPY VERSUS STANDARD ADJUVANT ENDOCRINE THERAPY ALONE FOR HR OR HER2 EARLY BREAST CANCER WI203696 | No dispute reported | 06/30/2026 | 1228710806 |
| Principal investigator 1 | PFIZER INC. | $500.00 | 01/30/2025 | Covered Recipient Teaching Hospital Langley Porter Psychiatric Hospital | PALLASPALBOCICLIB COLLABORATIVE ADJUVANT STUDYA RANDOMIZED PHASE III TRIAL OF PALBOCICLIB WITH STANDARD ADJUVANT ENDOCRINE THERAPY VERSUS STANDARD ADJUVANT ENDOCRINE THERAPY ALONE FOR HR OR HER2 EARLY BREAST CANCER WI203696 | No dispute reported | 06/30/2026 | 1228710808 |
| Principal investigator 1 | PFIZER INC. | $500.00 | 01/30/2025 | Covered Recipient Teaching Hospital Langley Porter Psychiatric Hospital | PALLASPALBOCICLIB COLLABORATIVE ADJUVANT STUDYA RANDOMIZED PHASE III TRIAL OF PALBOCICLIB WITH STANDARD ADJUVANT ENDOCRINE THERAPY VERSUS STANDARD ADJUVANT ENDOCRINE THERAPY ALONE FOR HR OR HER2 EARLY BREAST CANCER WI203696 | No dispute reported | 06/30/2026 | 1228710810 |
| Recipient | PFIZER INC. | $330.00 | 01/28/2025 | Covered Recipient Physician | PALBOCICLIB CLINICAL PUBLICATION PROGRAM | No dispute reported | 06/30/2026 | 1228760773 |
| Recipient | PFIZER INC. | $330.00 | 01/28/2025 | Covered Recipient Physician | MAVELERTINIB CLINICAL PUBLICATION PROGRAM | No dispute reported | 06/30/2026 | 1228770488 |
| Recipient | PFIZER INC. | $330.00 | 01/28/2025 | Covered Recipient Physician | MAVELERTINIB CLINICAL PUBLICATION PROGRAM | No dispute reported | 06/30/2026 | 1228770886 |
| Recipient | PFIZER INC. | $330.00 | 01/27/2025 | Covered Recipient Physician | PALBOCICLIB CLINICAL PUBLICATION PROGRAM | No dispute reported | 06/30/2026 | 1228769275 |
| Principal investigator 1 | Hoffmann-La Roche Limited | $12,134.10 | 01/13/2025 | Covered Recipient Teaching Hospital Langley Porter Psychiatric Hospital | Morpheus Breast Cancer | No dispute reported | 06/30/2026 | 1211547156 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $7,170.35 | 01/09/2025 | Covered Recipient Teaching Hospital Langley Porter Psychiatric Hospital | DS8201-U-106 | No dispute reported | 06/30/2026 | 1223347422 |
| Principal investigator 1 | Eli Lilly and Company | $381.25 | 01/09/2025 | Non-covered Recipient Entity WASHINGTON HOSP. HEALTHCARE SYSTEM | EMBER-4: A RANDOMIZED, OPEN-LABEL, PHASE 3 STUDY OF ADJUVANT IMLUNESTRANT VS STANDARD ADJUVANT ENDOCRINE THERAPY IN PATIENTS WHO HAVE PREVIOUSLY RECEIVED 2 TO 5 YEARS OF ADJUVANT ENDOCRINE THERAPY FOR ER+, HER2- EARLY BREAST CANCER WITH AN INCREASED RISK OF RECURRENCE | No dispute reported | 06/30/2026 | 1187893786 |
| Principal investigator 1 | AstraZeneca Pharmaceuticals LP | $339,276.44 | 01/03/2025 | Covered Recipient Teaching Hospital Langley Porter Psychiatric Hospital | Capivasertib plus Palbociclib plus Fulvestrant for HR/HER2 Advanced Breast Cancer CAPItello 292. | No dispute reported | 06/30/2026 | 1185544155 |